We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
ABL Bio, Inc. announced that the Investigational New Drug (IND) application for ABL501 has been approved by South Korea's Ministry of Food and Drug Safety (MFDS).